<code id='390133EAF9'></code><style id='390133EAF9'></style>
    • <acronym id='390133EAF9'></acronym>
      <center id='390133EAF9'><center id='390133EAF9'><tfoot id='390133EAF9'></tfoot></center><abbr id='390133EAF9'><dir id='390133EAF9'><tfoot id='390133EAF9'></tfoot><noframes id='390133EAF9'>

    • <optgroup id='390133EAF9'><strike id='390133EAF9'><sup id='390133EAF9'></sup></strike><code id='390133EAF9'></code></optgroup>
        1. <b id='390133EAF9'><label id='390133EAF9'><select id='390133EAF9'><dt id='390133EAF9'><span id='390133EAF9'></span></dt></select></label></b><u id='390133EAF9'></u>
          <i id='390133EAF9'><strike id='390133EAF9'><tt id='390133EAF9'><pre id='390133EAF9'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:explore    - browse:378
          Alastair Grant/AP

          LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

          The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

          advertisement

          AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus